Maen Abdelrahim is an Oncology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6445 Main Street, Opc24
Houston, TX 77030
Telephone
713-441-9948Registry record last updated 17 Mar 2018.
Clinical trials
- Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer
Sponsor: The Methodist Hospital Research Institute
- 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
Sponsor: The Methodist Hospital Research Institute
- Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients
Sponsor: The Methodist Hospital Research Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
33 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Astellas Pharma US IncProgram year202566 payments$85,740openpaymentsdata.cms.gov ↗
- Takeda Pharmaceuticals U.S.A., Inc.Program year202541 payments$80,880openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202528 payments$45,662openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
31.4%Serotonin-3 Receptor Antagonist23.8%Ondansetron Odt68%Ondansetron Hcl32%Part D≥26 patientsProton pump inhibitor7.5%Pantoprazole Sodium100%Part D<11 patientsNervous system
27.6%Phenothiazine17.6%Prochlorperazine Maleate100%Part D≥29 patientsOther antidepressants5.4%Mirtazapine100%Part D≥11 patients+ 1 more class in this area
Cancer & immunology
20.1%Kinase inhibitor20.1%Lenvima54%Imatinib Mesylate46%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2023–2026 per NIH RePORTER. The latest:
- NR4A1 Antagonists Inhibit Colorectal Cancer Growth and Enhance Immune Surveillance
Texas A&m University
FY2026$569,849R01CA269580 - NR4A1 Antagonists Inhibit Colorectal Cancer Growth and Enhance Immune Surveillance
Texas A&m University
FY2025$571,380R01CA269580 - NR4A1 Antagonists Inhibit Colorectal Cancer Growth and Enhance Immune Surveillance
Texas A&m University
FY2024$543,717R01CA269580
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”